Login
Home
Charts
Search
Watchlist
Products

Galaxy Surfactants Ltd

GALAXYSURF·NSE
2,188.00-0.02%Tue, 22 Sept '26 15:50

Galaxy Surfactants Ltd

GALAXYSURF
NSE
2,188.00
-0.02%
|Tue, 22 Sept '26 15:50
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
7,768Cr
Close
Close Price
2,191.00
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
21.96
PS
Price To Sales
1.35
Revenue
Revenue
5,752Cr
Rev Gr TTM
Revenue Growth TTM
27.05%
PAT Gr TTM
PAT Growth TTM
16.13%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9839409299741,0631,0421,1451,2781,3261,3291,3151,782
Growth YoY
Revenue Growth YoY%
-20.2-13.3-5.23.48.110.823.231.224.827.614.839.4
Expenses
ExpensesCr
8588288278509359361,0181,1541,2161,2101,1931,533
Operating Profit
Operating ProfitCr
125112102124128106127124111119122249
OPM
OPM%
12.712.010.912.712.010.111.19.78.39.09.314.0
Other Income
Other IncomeCr
36245948116-703
Interest Expense
Interest ExpenseCr
565445677989
Depreciation
DepreciationCr
252526272828282930313336
PBT
PBTCr
988894991047710099797380207
Tax
TaxCr
201616192012242013141841
PAT
PATCr
7771788085657679665962166
Growth YoY
PAT Growth YoY%
-7.7-32.8-14.46.09.4-9.5-2.1-0.3-21.5-8.7-17.7108.7
NPM
NPM%
7.97.68.38.28.06.26.66.25.04.44.89.3
EPS
EPS
21.820.121.922.523.918.221.422.418.816.617.646.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9839409299741,0631,0421,1451,2781,3261,3291,3151,782
Growth YoY
Revenue Growth YoY%
-20.2-13.3-5.23.48.110.823.231.224.827.614.839.4
Expenses
ExpensesCr
8588288278509359361,0181,1541,2161,2101,1931,533
Operating Profit
Operating ProfitCr
125112102124128106127124111119122249
OPM
OPM%
12.712.010.912.712.010.111.19.78.39.09.314.0
Other Income
Other IncomeCr
36245948116-703
Interest Expense
Interest ExpenseCr
565445677989
Depreciation
DepreciationCr
252526272828282930313336
PBT
PBTCr
988894991047710099797380207
Tax
TaxCr
201616192012242013141841
PAT
PATCr
7771788085657679665962166
Growth YoY
PAT Growth YoY%
-7.7-32.8-14.46.09.4-9.5-2.1-0.3-21.5-8.7-17.7108.7
NPM
NPM%
7.97.68.38.28.06.26.66.25.04.44.89.3
EPS
EPS
21.820.121.922.523.918.221.422.418.816.617.646.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,8012,1612,4342,7632,5962,7843,6864,4643,7944,2245,2485,752
Growth
Revenue Growth%
-3.820.012.613.5-6.07.232.421.1-15.011.324.327.1
Expenses
ExpensesCr
1,5691,8902,1462,4102,2272,3353,2853,8963,3323,7414,7835,152
Operating Profit
Operating ProfitCr
232271288353369449401568462483466601
OPM
OPM%
12.912.611.812.814.216.110.912.712.211.48.910.4
Other Income
Other IncomeCr
61010561113103527202
Interest Expense
Interest ExpenseCr
312731302413132222193134
Depreciation
DepreciationCr
4547495162747183100110123130
PBT
PBTCr
161207219277289372329473375380332440
Tax
TaxCr
606061865870679274766486
PAT
PATCr
101148158191230302263381301305267354
Growth
PAT Growth%
48.746.07.020.920.631.1-13.045.0-20.91.1-12.316.1
NPM
NPM%
5.66.86.56.98.910.87.18.58.07.25.16.2
EPS
EPS
28.541.644.653.965.085.274.1107.585.086.075.499.8
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,8012,1612,4342,7632,5962,7843,6864,4643,7944,2245,2485,752
Growth
Revenue Growth%
-3.820.012.613.5-6.07.232.421.1-15.011.324.327.1
Expenses
ExpensesCr
1,5691,8902,1462,4102,2272,3353,2853,8963,3323,7414,7835,152
Operating Profit
Operating ProfitCr
232271288353369449401568462483466601
OPM
OPM%
12.912.611.812.814.216.110.912.712.211.48.910.4
Other Income
Other IncomeCr
61010561113103527202
Interest Expense
Interest ExpenseCr
312731302413132222193134
Depreciation
DepreciationCr
4547495162747183100110123130
PBT
PBTCr
161207219277289372329473375380332440
Tax
TaxCr
606061865870679274766486
PAT
PATCr
101148158191230302263381301305267354
Growth
PAT Growth%
48.746.07.020.920.631.1-13.045.0-20.91.1-12.316.1
NPM
NPM%
5.66.86.56.98.910.87.18.58.07.25.16.2
EPS
EPS
28.541.644.653.965.085.274.1107.585.086.075.499.8

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
3535353535353535353535
Reserves
ReservesCr
4065396838411,0321,2661,5391,8472,1442,3272,709
Current Liabilities
Current LiabilitiesCr
4355496295595696208656806039781,016
Non Current Liabilities
Non Current LiabilitiesCr
223163107132175128161172132121113
Total Liabilities
Total LiabilitiesCr
1,1001,2871,4551,5681,8122,0492,6012,7342,9153,4623,874
Current Assets
Current AssetsCr
5847569198979351,1581,5701,6021,7022,0942,443
Non Current Assets
Non Current AssetsCr
5175315376718778921,0301,1331,2131,3691,431
Total Assets
Total AssetsCr
1,1001,2871,4551,5681,8122,0492,6012,7342,9153,4623,874
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
3535353535353535353535
Reserves
ReservesCr
4065396838411,0321,2661,5391,8472,1442,3272,709
Current Liabilities
Current LiabilitiesCr
4355496295595696208656806039781,016
Non Current Liabilities
Non Current LiabilitiesCr
223163107132175128161172132121113
Total Liabilities
Total LiabilitiesCr
1,1001,2871,4551,5681,8122,0492,6012,7342,9153,4623,874
Current Assets
Current AssetsCr
5847569198979351,1581,5701,6021,7022,0942,443
Non Current Assets
Non Current AssetsCr
5175315376718778921,0301,1331,2131,3691,431
Total Assets
Total AssetsCr
1,1001,2871,4551,5681,8122,0492,6012,7342,9153,4623,874

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1701111452833163655573518421333
Investing Cash Flow
Investing Cash FlowCr
-59-43-55-167-151-165-84-149-344-295-378
Financing Cash Flow
Financing Cash FlowCr
-110-57-90-119-144-16559-264-189-157-51
Net Cash Flow
Net Cash FlowCr
0111-42135-20160-14-31-96
Free Cash Flow
Free Cash FlowCr
1776889115174258-150429362239198
CFO To PAT
CFO To PAT%
167.875.292.0148.2137.1120.81.9150.4172.0137.9124.4
CFO To EBITDA
CFO To EBITDA%
73.240.950.580.185.681.31.2100.8112.287.171.4
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1701111452833163655573518421333
Investing Cash Flow
Investing Cash FlowCr
-59-43-55-167-151-165-84-149-344-295-378
Financing Cash Flow
Financing Cash FlowCr
-110-57-90-119-144-16559-264-189-157-51
Net Cash Flow
Net Cash FlowCr
0111-42135-20160-14-31-96
Free Cash Flow
Free Cash FlowCr
1776889115174258-150429362239198
CFO To PAT
CFO To PAT%
167.875.292.0148.2137.1120.81.9150.4172.0137.9124.4
CFO To EBITDA
CFO To EBITDA%
73.240.950.580.185.681.31.2100.8112.287.171.4

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,3183,7894,1579,05910,1608,2728,0467,2735,3707,768
Price To Earnings
Price To Earnings
33.619.818.030.038.721.726.723.920.122.0
Price To Sales
Price To Sales
2.21.41.63.32.81.92.11.71.01.4
Price To Book
Price To Book
7.44.33.97.06.54.43.73.12.02.8
EV To EBITDA
EV To EBITDA
19.411.412.120.626.214.717.315.111.413.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
30.426.925.326.730.533.126.927.728.628.522.822.8
OPM
OPM%
12.912.611.812.814.216.110.912.712.211.48.910.4
NPM
NPM%
5.66.86.56.98.910.87.18.58.07.25.16.2
ROCE
ROCE%
24.825.824.727.222.224.317.122.416.815.512.212.2
ROE
ROE%
22.925.722.021.821.623.216.720.213.812.99.79.7
ROA
ROA%
9.211.510.912.212.714.710.113.910.38.86.96.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,3183,7894,1579,05910,1608,2728,0467,2735,3707,768
Price To Earnings
Price To Earnings
33.619.818.030.038.721.726.723.920.122.0
Price To Sales
Price To Sales
2.21.41.63.32.81.92.11.71.01.4
Price To Book
Price To Book
7.44.33.97.06.54.43.73.12.02.8
EV To EBITDA
EV To EBITDA
19.411.412.120.626.214.717.315.111.413.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
30.426.925.326.730.533.126.927.728.628.522.822.8
OPM
OPM%
12.912.611.812.814.216.110.912.712.211.48.910.4
NPM
NPM%
5.66.86.56.98.910.87.18.58.07.25.16.2
ROCE
ROCE%
24.825.824.727.222.224.317.122.416.815.512.212.2
ROE
ROE%
22.925.722.021.821.623.216.720.213.812.99.79.7
ROA
ROA%
9.211.510.912.212.714.710.113.910.38.86.96.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Galaxy Surfactants is the chemical engine inside the world’s everyday hygiene and beauty routines - it makes the ingredients that create the lather in your shampoo, the cleansing power in your detergent, and the conditioning feel in your moisturiser. Founded in 1980 by five individuals and built over four decades of exclusive focus on the home and personal care (HPC) industry, the company has grown from an import-substitution player in a closed Indian economy into a global supplier serving over 1,500 clients across 95 countries. Everything it does is shaped by a “Consumer to Chemistry” philosophy: it spots what consumers want next - gentler cleansers, greener preservatives, sulfate-free formulations - and then co-develops the molecules with its customers before the trend becomes mainstream. # Business segments A single integrated business built on two product families - high-volume Performance Surfactants that provide the basic cleansing function, and higher-value Specialty Care Products that deliver targeted benefits like conditioning, preservation, and UV protection - both sold to the same global FMCG and personal-care customers from the same manufacturing backbone. ## 1. Performance Surfactants: the volume engine that pays the bills **These are the workhorse cleansing and foaming agents that go into nearly every rinse-off product on the shelf - shampoos, body washes, laundry detergents, and dishwashing liquids - sold in large tonnages to FMCG giants on a cost-plus-pass-through model.** - **The chemistry of clean** - Performance Surfactants are the substantive raw materials that deliver the functional requirement of cleanliness, forming the backbone of rinse-off formulations across home and personal care. The portfolio spans 47-plus product grades and accounted for roughly 1,67,000 metric tonnes of the company’s total group volume of about 2,57,000 MT in FY25 - roughly two-thirds of every tonne shipped. - **Pulled by everyday consumption** - demand is driven by the relative inelasticity of the HPC industry: people keep washing their hands, doing laundry, and cleaning dishes regardless of economic cycles, so FMCG companies keep ordering. The business model relies on volume growth combined with a gradual shift toward higher-margin specialty grades within the mix to improve per-tonne profitability. - **Priced with a pass-through, not a guess** - these products are sold primarily on a per-tonne basis, with raw-material and freight cost increases passed through to customers, though with a time lag that creates short-term margin swings. Key raw materials - Fatty Alcohol and Fatty Acids derived from Crude Palm Kernel Oil - make up 55-60% of procurement and are sourced from multiple suppliers across Indonesia, Malaysia, and Thailand. - **Three-continent manufacturing footprint** - the Taloja plant in Maharashtra is one of India’s largest sulfation facilities with 156,741 MTPA capacity and easy access to the Jawaharlal Nehru port; Jhagadia in Gujarat adds 132,750 MTPA and sits close to the ethylene oxide raw-material source; and the Suez, Egypt facility contributes 117,500 MTPA from a tax-exempt free zone with direct Suez Canal access to serve Africa, the Middle East, Europe, and the Americas. - **Reformulation pressure, met with alternatives** - in India, key Tier 1 customers reformulated products during FY26, causing volume losses, but those were fully offset by growth in non-Tier 1 and direct-to-consumer accounts, and the company is already producing and selling an alternative surfactant system that is gaining market share. In the AMET region, logistics disruptions from the West Asia conflict and competition from a local backward-integrated player in Egypt have pressured volumes. ## 2. Specialty Care Products: the higher-value growth platform **These are niche, premium ingredients that do more than clean - they condition hair, preserve formulations without toxic chemicals, protect skin from UV damage, and create the sensory experience consumers now demand - and they command higher margins because each one solves a specific, hard-to-replicate problem.** - **Functionality beyond foam** - Specialty Care Products deliver tailored benefits including conditioning, moisturisation, anti-bacterial action, sensory enhancement, preservation, and UV protection, going into personal care, home care, and beauty formulations. The portfolio is the company’s most diverse, with 168-plus product grades, and contributed about 89,000 metric tonnes of group volume in FY25. - **Low volume, high value, oligopolistic markets** - these ingredients are consumed in small quantities per application and operate in markets with few competitors and low penetration because of their unique application requirements, which means pricing power is stronger than in the commoditised Performance segment. Specialty volumes grew roughly 13-14% in FY24 and delivered more than 27% volume growth in India in FY26, making mix improvement toward specialties the core driver of per-tonne profitability. - **Mild Surfactants - ahead of the sulfate-free wave** - the company developed sulfate-free, PEG-free, and amino-acid-based cleansing agents well before market demand surged, including Galsoft SLL, a COSMOS-certified, 100% naturally-derived ingredient, and Galsoft Lumithic, a self-thickening amino-acid-based surfactant launched in FY26 that simplifies formulation for sensitive applications like baby care and feminine hygiene. - **Preservatives without the toxicity** - the Galguard range includes patented, non-toxic antimicrobial technologies developed in-house: Galguard Lipo G won the Indian Chemical Council’s Acharya P.C. Ray Award for indigenous technology, and Galguard Prebiotive won the In-cosmetics Global 2025 Innovation Zone Best Ingredient Award 2025. These products address the industry’s urgent need to replace traditional preservatives that face growing regulatory and consumer pressure. - **Innovation funnel feeds the pipeline** - an Innovation Funnel adopted in 2007 systematically converts consumer trends into commercial products, supported by an R&D centre with over 100 professionals including doctorates, chemists, and engineers, and a dedicated pilot plant at Tarapur for scaling up new molecules from lab to factory. The company holds 111 approved patents with 32 more applied for, and won the Silver Award at In-Cosmetics Global in Paris - the only Indian and Asian company to do so. # Manufacturing, R&D and supply chain **Seven plants across three continents, in-house project execution that avoids dependence on external engineering firms, and a sustainability programme that already makes the company water-positive - this is the operational backbone that lets both product families reach customers with consistent quality and cost.** - **Plants placed where the raw materials and ports are** - the five Indian facilities include Taloja (one of India’s largest sulfation plants, near the port), Jhagadia (close to the ethylene oxide source), and three units at Tarapur including a pilot plant for new-product scale-up; the Egypt plant sits in a tax-exempt free zone on the Suez Canal; and the US facility in New Hampshire produces protein grades for cosmetics. Environmental clearances and additional land are already secured at Jhagadia and Suez for future expansion. - **Built, not bought** - the company developed in-house project execution capability and built its own continuous-process sulphonation plants in 2004 without external engineering support, an edge it has sharpened over two decades and now deploys for all capacity expansions. It typically invests around ₹150-200 Crores in capex every year, evaluating threshold capacity levels across production lines. - **Green chemistry by design** - the company follows the 12 principles of Green Chemistry in product development and has conducted Life Cycle Assessments for multiple products on a cradle-to-gate basis. All Indian manufacturing units have been Zero Liquid Discharge since 2017, meaning no industrial wastewater leaves the factory, and the company is certified as 1.4x water-positive - it restores more water than it consumes. - **Supply chains under geopolitical strain** - the West Asia conflict and Red Sea disruptions caused sharp escalations in input costs, rerouting of sea freight, and delays in both inbound raw materials and outbound export shipments, particularly affecting the Egypt facility and AMET volumes. The company maintains strategic long-term tie-ups with shipping lines and runs a “Global Customer Delight” process to coordinate supply-chain responses. # Group structure and partners **A professionally managed Indian parent with eight wholly-owned subsidiaries spanning manufacturing in Egypt and the US, distribution in Europe and Latin America, and a new strategic move into providing plant-design services to a global customer - the structure mirrors the global footprint of the FMCG clients it serves.** - **Distribution subsidiaries open doors in new markets** - Galaxy Specialties Europe B.V. was incorporated in Amsterdam on March 1, 2025 to enhance supply-chain agility for specialty ingredients in Europe, while Galaxy Surfactants Mexico and Tri-k Mexico were set up in late 2024 to further business interests across surfactants, specialty ingredients, and proteins in Latin America. - **From ingredient supplier to plant builder** - in March 2025, the company entered a strategic collaboration with a global customer to provide EPC services - process design, procurement, engineering, construction, and commissioning - for the customer’s Performance Surfactants and Specialty Ingredients plant at an overseas location, and is in advanced discussions to deepen the collaboration post-commissioning. This marks a new capability being monetised beyond the core manufacturing business. - **Leadership transitioned from founders to professionals** - the Managing Director (K. Natarajan, 30-year tenure) and Executive Director & COO (Vaijanath Kulkarni, 28-year tenure, who built the Egypt operations) lead a professionally managed structure that completed its founder-to-professional transition in FY24 when the promoter and former Managing Director moved to a non-executive role.

Documents — Galaxy Surfactants Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/8c2n6odo35lf45cmjt37s7ks.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/u0q6pkqkccce3mg7rrn2iavs.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/hgn4mjojy66f8fi3r065c2ap.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/ltbjsj7blpmvkh691f2wvbkg.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/nrpj1bgjhtlku9j9spd852pj.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/ekvt7hv7vh4jkvuqbhqkzlxy.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/39ef8mtqwf1pxdkudm8wkyca.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/1707agg25lufycs9nlkukem6.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/m5twujmttm9fw4dvews8kzjw.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/mvp4uh8lqnhwtvh4afdu2fj9.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/2qgiaw3l8dge9egbezyrpdbu.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/vpxwrk4y3w7ypk973uk16ec9.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/fk91fa5jf9uz0zblx5x6eace.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/fzvxgt922dpxicti3d0w8hi1.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/tu1pjeup2z7aedthrx46p8zn.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/95azjnoaniq7uaz0162up79f.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/vdp27q2vgqicx2plfzqbamu3.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/e1dlrnuyvf1zf8fhpxv52h8u.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/ik75itq4kw1t5956ytm9sjx9.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/wv3vpiu5ik3fx5pou6ibrao1.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/q5oqrwifw51vvwe2c7wmga0y.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/4qk3s8nb0fwl5poq6r6q5cnm.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/xn5gs4ghsyp2291z4u0ilw1f.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/9zkvjx0q9o4xawobc4lrg8bf.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/3sra0z1v346noiinufxcm506.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/bl7ao18670bcdmn1skr7bxuk.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/j5bi1mvqgugmduavf5zoxomu.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/2mthjjyqqeb3s5nme3ckl7sp.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/od7bkjpwqgm8o6tuupkfygh8.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/o5uv4z23pspo7pd1umbukuxu.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/3amwcpr682nhk1dsm197cdak.pdf

Concall Transcript Summaries — Galaxy Surfactants Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202606/8c2n6odo35lf45cmjt37s7ks.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202603/u0q6pkqkccce3mg7rrn2iavs.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202512/hgn4mjojy66f8fi3r065c2ap.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202509/ltbjsj7blpmvkh691f2wvbkg.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202506/nrpj1bgjhtlku9j9spd852pj.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202503/ekvt7hv7vh4jkvuqbhqkzlxy.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202412/39ef8mtqwf1pxdkudm8wkyca.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AGALAXYSURF/transcript-notes/202409/1707agg25lufycs9nlkukem6.pdf